Menu
← Oncology Approval Tracker
FDA DECISION ·
Tivdak
tisotumab vedotin-tftv · Seagen
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with recurrent or metastatic cervical cancer whose disease progressed during or after chemotherapy.
LAMPGEN ANALYSIS
Why it matters
The initial accelerated action introduced a tissue factor-directed antibody-drug conjugate. FDA later granted traditional approval on April 29, 2024.
What research teams should watch
Coordinate eye examinations and preventive eye care with infusions and document prior chemotherapy progression.
PRIMARY RECORDS